GV 2207

Drug Profile

GV 2207

Alternative Names: GV2207; HSV-2 vaccine - GenVec

Latest Information Update: 29 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GenVec
  • Developer GenVec; National Institute of Allergy and Infectious Diseases
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Herpes simplex virus infections

Most Recent Events

  • 16 Jun 2017 GenVec was acquired by Intrexon Corporation
  • 24 Feb 2017 GV 2207 is still available for partnering for further development (http://www.genvec.com) (GenVec's form 10-K, filed in March 2017)
  • 28 Mar 2014 Discontinued - Preclinical for Herpes simplex virus infections (prevention) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top